• 1
    RiesLAG,SmithMA,GurneyJG,LinetM,TamraT,YoungJL,BuninG, eds. Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995. Bethesda, MD: National Cancer Institute, SEER Program, 1999. NIH Publication Number 99-4649. National Cancer Institute, SEER Program.
  • 2
    Garwicz S,Anderson H,Olsen JH,Dollner H,Hertz H,Jonmundsson G,Langmark F,Lanning M,Moller T,Sankila R,Tulinius H. Second malignant neoplasms after cancer in childhood and adolescence: a population-based case-control study in the 5 Nordic countries. The Nordic Society for Pediatric Hematology and Oncology. The Nordic Association of Cancer Registries. Int J Cancer 2000; 88: 67288.
  • 3
    Neglia JP,Friedman DL,Yasui Y,Mertens AC,Hammond S,Stovall M,Donaldson SS,Meadows AT,Robison LL. Second malignant neoplasms in five-year survivors of childhood cancer: Childhood Cancer Survivor Study. J Natl Cancer Inst 2001; 93: 61829.
  • 4
    Friedman DL,Meadows AT. Pediatric tumors. In: NeugutAI.,MeadowsAT,RobinsonE. eds. Multiple primary cancers. Philadelphia, PA: Lippincott Williams & Wilkins, 1999. 23556.
  • 5
    Bhatia S. Late effects among survivors of childhood leukemia during childhood and adolescence. Blood Cells Mol Dis 2003; 31: 8492.
  • 6
    Bhatia S,Sklar C. Second cancers in survivors of childhood cancer. Nat Rev Cancer 2002: 2; 124132.
  • 7
    Jenkinson HC,Hawkins MM,Stiller CA,Winter DL,Marsden HB,Stevens MC. Long-term population-based risks of second malignant neoplasms after childhood cancer in Britain. Br J Cancer 2004; 91: 190510.
  • 8
    Harlan LC,Hankey BF. The surveillance, epidemiology, and end-results program database as a resource for conducting descriptive epidemiologic and clinical studies. J Clin Oncol 2003; 21: 22549.
  • 9
    RiesLAG,EisnerMP,KosaryCL,HankeyBF,MillerBA,CleggL,MariottoA,FeuerEJ,EdwardsBK, eds. SEER cancer statistics review, 1975–2001. Bethesda, MD: National Cancer Institute. Available at,2004.
  • 10
    JohnsonCH, ed. The SEER coding and staging manual 2004, revision 1. Bethesda, MD: National Cancer Institute, NIH, 2004. NIH Publication Number 045581.
  • 11
    Kramarova E,Stiller CA. The international classification of childhood cancer. Int J Cancer 1996; 68: 75965.
  • 12
    Gooley TA,Leisenring W,Crowley J,Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695706.
  • 13
    Yasui Y,Liu Y,Neglia JP,Friedman DL,Bhatia S,Meadows AT,Diller LR,Mertens AC,Whitton J,Robison LL. A methodological issue in the analysis of second-primary cancer incidence in long-term survivors of childhood cancers. Am J Epidemiol 2003; 158: 110813.
  • 14
    Olsen JH,Garwicz S,Hertz H,Jonmundsson G,Langmark F,Lanning M,Lie SO,Moe PJ,Møller T,Sankila R,Tulinius H, Nordic Society of Paediatric Haematology and Oncology Association of the Nordic Cancer Registries. Second malignant neoplasms after cancer in childhood or adolescence. BMJ 1993; 307: 103036.
  • 15
    Tucker MA,Coleman CN,Cox RS,Varghese A,Rosenberg SA. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 1988; 318: 7681.
  • 16
    Hancock SL,Tucker MA,Hoppe RT. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 1993; 85: 2531.
  • 17
    Bhatia S,Robison LL,Oberlin O,Greenberg M,Bunin G,Fossati-Bellani F,Meadows AT. Breast cancer and other second neoplasms after childhood Hodgkin disease. N Engl J Med 1996; 334: 74551.
  • 18
    van Leeuwen FE,Klokman WJ,Veer MB,Hagenbeek A,Krol AD,Vetter UA,Schaapveld M,van Heerde P,Burgers JM,Somer R,Aleman BM. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 2000; 18: 48797.
  • 19
    van Leeuwen FE,Klokman WJ,Stovall M,Dahler EC,van't Veer MB,Noordijk EM,Crommelin MA,Aleman BM,Broeks A,Gospodarowicz M,Travis LB. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003; 95: 97180.
  • 20
    Metayer C,Lynch CF,Clarke EA,Glimelius B,Storm H,Pukkala E,Joensuu T,van Leeuwen FE,van't Veer MB,Curtis RE,Holowaty EJ,Andersson M, et al. Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. J Clin Oncol 2000; 18: 243543.
  • 21
    Bhatia S,Yasui Y,Robison LL,Birch JM,Bogue MK,Diller L,DeLaat C,Fossati-Bellani F,Morgan E,Oberlin O,Reaman G,Ruymann FB, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol 2003; 21: 438694.
  • 22
    Tucker MA,Meadows AT,Boice JDJr,Stovall M,Oberlin O,Stone BJ,Birch J,Voute PA,Hoover RN,Fraumeni JFJr. Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst 1987; 78: 45964.
  • 23
    Hawkins MM,Wilson LM,Stovall MA,Marsden HB,Potok MH,Kingston JE,Chessells JM. Epipodophyllotoxins, alkylating agents and radiation risk of secondary leukaemia after childhood cancer. BMJ 1992; 304: 9518.
  • 24
    van Leeuwen FE,Chorus AM,van den Belt-Dusebout AW,Hagenbeek A,Noyon R,van Kerkhoff EH,Pinedo HM,Somers R. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 1994; 12: 106373.
  • 25
    Heyn R,Khan F,Ensign LG,Donaldson SS,Ruymann F,Smith MA,Vietti T,Maurer HM. Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on Intergroup Rhabdomyosarcoma Study III: an interim report. Med Pediatr Oncol 1994; 23: 99106.
  • 26
    Leung W,Sandlund JT,Hudson MM,Zhou Y,Hancock ML,Zhu Y,Ribeiro RC,Rubnitz JE,Kun LE,Razzouk B,Evans WE,Pui CH. Second malignancy after treatment of childhood non-Hodgkin lymphoma. Cancer 2001; 92: 195966.
  • 27
    Little MP,Hawkins MM,Shore RE,Charles MW,Hildreth NG. Time variations in the risk of cancer following irradiation in childhood. Radiat Res 1991; 126: 30416.
  • 28
    Little MP,de Vathaire F,Charles MW,Hawkins MM,Muirhead CR. Variations with time and age in the risks of solid cancer incidence after radiation exposure in childhood. Stat Med 1998; 17: 134155.
  • 29
    de Vathaire F,Hawkins M,Campbell S,Oberlin O,Raquin MA,Schlienger JY,Shamsaldin A,Diallo I,Bell J,Grimaud E,Hardiman C,Lagrange JL, et al. Second malignant neoplasms after a first cancer in childhood: temporal pattern of risk according to type of treatment. Br J Cancer 1999; 79: 188493.
  • 30
    Tucker MA,D'Angio GJ,Boice JDJr,Strong LC,Li FP,Stovall M,Stone BJ,Green DM,Lombardi F,Newton W,Hoover RN,Fraumeni JFJr, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987; 317: 58893.
  • 31
    Tucker MA,Morris Jones PH,Boice JD,Jr,Robison LL,Stone BJ,Stovall M,Jenkin RD,Lubin JH,Baum ES,Siegel SE,Meadows AT,Hoover RN, et al. Therapeutic irradiation at a young age is linked to secondary thyroid cancer. Cancer Res 1991; 51: 28858.
  • 32
    Ron E,Modan B,Boice JD,Jr,Alfandary E,Stovall M,Chetrit A,Katz L. Tumors of the brain and central nervous system after radiotherapy in childhood. N Engl J Med 1988; 319: 10339.
  • 33
    Ron E,Lubin JH,Shore RE,Mabuchi K,Modan B,Pottern LM,Schneider AB,Tucker MA,Boice JDJr., Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 1995; 141: 25977.
  • 34
    Neglia JP,Meadows AT,Robison LI,Kim TH,Newton WA,Ruymann FB,Sather HN,Hammond GD. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 325: 13306.
  • 35
    Newton WA,Meadows AT,Shimada H,Bunin GR,Vawter GF. Bone sarcomas as a second malignant neoplasm following childhood cancer. Cancer 1991; 67: 193201.
  • 36
    Little MP,de Vathaire F,Shamsaldin A,Oberlin O,Campbell S,Grimaud E,Chavaudra J,Haylock RG,Muirhead CR. Risks of brain tumour following treatment for cancer in childhood: modification by genetic factors, radiotherapy and chemotherapy. Int J Cancer 1998; 78: 26975.
  • 37
    Hawkins MM,Wilson LMK,Burton HS,Potock MH,Winter DL,Marsden HB,Stovall MA. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst 1996; 88: 2708.
  • 38
    Kuttesch JF,Wexler LH,Marcus RB,Fairclough D,Weaver-McClure L,White M,Mao L,Delaney TF,Pratt CB,Horowitz ME,Kun LE. Second malignancies after Ewing's sarcoma: radiation and dose-dependency of secondary sarcomas. J Clin Oncol 1996; 14: 281825.
  • 39
    Wong FL,Boice JDJr,Abramson DH,Tarone RE,Kleinerman RA,Stovall M,Goldman MB,Seddon JM,Tarbell N,Fraumeni JF,Jr,Li FP. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 1997; 278: 12627.
  • 40
    Dunst J,Ahrens S,Paulussen M,Rube C,Winkelmann W,Zoubek A,Harms D,Jurgens H. Second malignancies after treatment for Ewing's sarcoma: a report of the CESS studies. Int J Radiat Oncol Biol Phys 1998; 42: 37984.
  • 41
    Karlsson P,Holmberg E,Lundell M,Mattson A,Holm LE,Wallgren A. Intracranial tumors after exposure to ionizing radiation during infancy: a pooled analysis of two Swedish cohorts of 28,008 infants with skin hemangioma. Radiat Res 1998; 150: 35764.
  • 42
    Le Vu B,de Vathaire F,Shamsaldin A,Hawkins MM,Grimaud E,Hardiman C,Diallo I,Vassal G,Bessa E,Campbell S,Panis X,Daly-Schveitzer N, et al. Radiation dose, chemotherapy, and risk of osteosarcoma after solid tumors during childhood. Int J Cancer 1998; 77: 3707.
  • 43
    Schneider AB,Lubin J,Ron E,Abrahams C,Stovall M,Goel A,Shore-Freedman E,Gierlowski TC. Salivary gland tumors after childhood radiation treatment for benign conditions of the head and neck: dose-response relationships. Radiat Res 1998; 149: 62530.
  • 44
    Walter AW,Hancock ML,Pui CH,Hudson MM,Ochs JS,Rivera GK,Pratt CB,Boyett JM,Kun LE. Secondary brain tumors in children treated for acute lymphoblastic leukemia at St. Jude Children's Research Hospital. J Clin Oncol 1998; 16: 37617.
  • 45
    de Vathaire F,Hardiman C,Shamsaldin A,Campbell S,Grimaud E,Hawkins MM,Raquin M,Oberlin O,Diallo I,Zucker JM,Panis X,Lagrange JL, et al. Thyroid carcinomas after irradiation for a first cancer during childhood. Arch Intern Med 1999; 159: 271319.
  • 46
    Bhatia S,Sather HN,Pabustan OB,Trigg ME,Gaynon PS,Robison LL. Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood 2002; 99: 425764.
  • 47
    Sigurdson AJ,Ronckers CM,Mertens AC,Stovall M,Smith SA,Liu Y,Berkow RL,Hammond S,Neglia JP,Meadows AT,Sklar CA,Robison LL, et al. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. Lancet 2005; 365: 201423.
  • 48
    Neglia JP,Robison LL,Stovall M,Liu Y,Packer RJ,Hammond S,Yasui Y,Kasper CE,Mertens AC,Donaldson SS,Meadows AT,Inskip PD. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2006; 98: 152837.
  • 49
    Draper GJ,Sanders BM,Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br J Cancer 1986; 53: 66171.
  • 50
    Eng C,Li FP,Abramson DH,Ellsworth RM,Wong FL,Goldman MB,Seddon J,Tarbell N,Boice JDJr. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 1993; 85: 11218.
  • 51
    Kleinerman RA,Tucker MA,Tarone RE,Abramson DH,Seddon JM,Stovall M,Li FP,Fraumeni JFJr, Risk of new cancers following radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol 2005; 23: 22729.
  • 52
    Moll AC,Imhof SM,Schouten-Van Meeteren,Kuik DJ,Hofman P,Boers M. Second primary tumors in hereditary retinoblastoma: a register-based study, 1945–1997. Is there evidence of an age effect on radiation-related risk. Ophthalmology 2001; 108: 110914.
  • 53
    Fletcher O,Easton D,Anderson K,Gilham C,Jay M,Peto J. Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst 2004; 96: 35763.
  • 54
    Henderson TO,Whitton J,Stovall M,Mertens AC,Mitby P,Friedman D,Strong LC,Hammond S,Neglia JP,Meadows AT,Robison L,Diller L. Secondary sarcomas in childhood cancer survivors: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2007; 99: 3008.
  • 55
    Moppett J,Oakhill A,Duncan AW. Second malignancies in children: the usual suspects? Eur J Radiol 2001; 38: 23548.
  • 56
    Donaldson SS. Pediatric Hodgkin's disease -up, up, and beyond. Int J Radiat Oncol Biol Phys 2002; 54: 18.
  • 57
    Kalapurakal JR,Thomas PR. Pediatric radiotherapy. An overview. Radiol Clin North Am 1997; 35: 126580.
  • 58
    Shusterman S,Meadows AT. Long term survivors of childhood leukemia. Curr Opin Hematol 2000; 7: 21722.
  • 59
    Feig SA. Second malignant neoplasms after successful treatment of childhood cancers. Blood Cells Mol Dis 2001; 27: 6626.
  • 60
    Bassal M,Mertens AC,Taylor L,Neglia JP,Greffe B,Hammond S,Ronckers CM,Friedman DL,Stovall M,Yasui YY,Robison LL,Meadows AT, et al. Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the Childhood Cancer Survivors Study. J Clin Oncol 2006; 24: 47683.
  • 61
    Miller RW,Myers MH. Age distribution of epithelial and nonepithelial cancers. Lancet 1983; 2: 1250.
  • 62
    Meadows AT. Risk factors for second malignant neoplasms: report from the Late Effects Study Group. Bull Cancer 1988; 75: 12530.